Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects. We Value MIRA At $16.50 Using Discontinued Cash Flow Analysts And A 20% Discount Rate
關注MIRA Pharmaceuticals;Zacks Small-Cap Research表示,該公司正在開發一種與四氫大麻酚具有相同益處且沒有負面副作用的四氫大麻酚類似物。使用已停產的現金流分析師和20%的折扣率,我們將MIRA估值爲16.50美元